Omnia Education Launches Nationwide Educational Series on Breast Pain and Fibrocystic Breast Changes Affecting Half of all Women
Educational Series Is Designed to Improve Clinician Competencies in Identifying, Evaluating and Treating Patients
Fort Washington, PA, November 14, 2014
Omnia Education, the leading provider of women’s health continuing medical education (CME), today announced the launch of a nationwide educational series on breast pain and fibrocystic breast changes (FBC). Breast pain is the most common breast symptom for which women consult their physician. Approximately 45% of all women report mild breast pain while evidence shows more than half of all women experience FBC across their lifespan. Along with breast pain and tenderness, FBC may also cause nipple discharge and lumpiness or thickening of breast tissue. While the majority of breast problems are benign, the combination of symptoms present in FBC requires careful assessment by clinicians to rule out malignancies and to determine whether treatment is needed. As a result, it is essential that clinicians have access to the latest information on diagnosing these conditions, as well as the best treatment options available now and in the future.
“Managing Fibrocystic Breast Changes,” is a new medical education series designed by Omnia Education. The series is designed to help clinicians identify and evaluate patients who show symptoms of FBC and to understand their management options. Both hormonal and non-hormonal treatments are reviewed, along with a potential new paradigm of using molecular iodine to treat breast changes and breast pain.
“Breast pain is such a common complaint by our patients, and it requires assessment in all cases and treatment in many,” said Lee Philip Shulman, MD, Northwestern University Feinberg School of Medicine, Department of Obstetrics and Gynecology, a presenting faculty member in the series produced by Omnia Education. “Our focus is to ensure clinicians can identify and evaluate patients who show symptoms of FBC and that they fully understand the underlying causes of breast pain. For patients who require treatment, this program explores a variety of management options available today and takes a look at what is on the horizon.”
The FBC educational series is presented in seven locations nationwide through Omnia Education’s popular live meeting titled, “Women’s Health Annual Visit (WHAV)”. Each live WHAV meeting offers a full day of topics of interest to women’s health practitioners, including this FBC program. Also planned is an expert panel discussion featuring the opinions of faculty, accessible on ReachMD.com. More information is available at http://www.omniaeducation.com/WHAV.
“Managing Fibrocystic Breast Changes” is supported through an unrestricted educational grant from BioPharmX, a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets.
About Omnia Education
Omnia Education’s singular focus on the female patient has transformed the CME learning environment for healthcare professionals. Its CME program impacts thousands of clinicians annually through clinical updates and connectivity with regional and national peers, including its highly successful Women’s Health Annual Visit® and Stages in Women’s Health® conferences. More information is available at http://www.OmniaEducation.com.
About BioPharmX Corporation
BioPharmX Corporation (OTCQB: BPMX) is a Silicon Valley-based biotechnology company, which seeks to provide innovative products through unique, proprietary platform technologies for prescription, over-the-counter (“OTC”), and supplement applications in the fast-growing health and wellness markets, including women’s health, dermatology, and otolaryngology (ears, nose & throat). To learn more about BioPharmX, visit http://www.BioPharmX.com.
BioPharmX is a trademark of BioPharmX Corporation.